All In MedTech

FDA Clearance Tracker · P120005

DEXCOM G4 PLATINUM CONTIUOUS GLUCOSE MONITORING SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Oct 5, 2012 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Oct 5, 2012

Approval withdrawn

Time to decision

179 days

Received Apr 9, 2012. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P120005
Device name
DEXCOM G4 PLATINUM CONTIUOUS GLUCOSE MONITORING SYSTEM
Applicant
Dexcom, Inc.
Applicant location
San Diego, CA
Received
Apr 9, 2012
Decided
Oct 5, 2012
Decision
Approval withdrawn
Supplements
83 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MDS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE DEXCOM G4 PLATINUM CONTINUOUS GLUCOSE MONITORING SYSTEM. THIS DEVICE IS INDICATED FOR:THE DEXCOM G4 PLATINUM CONTINUOUS GLUCOSE MONITORING SYSTEM IS A GLUCOSE MONITORING DEVICE INDICATED FOR DETECTING TRENDS AND TRACKING PATTERNS IN PERSONS (AGE 18 AND OLDER) WITH DIABETES. THE SYSTEM IS INTENDED FOR SINGLE PATIENT USE AND REQUIRES A PRESCRIPTION.THE DEXCOM G4 PLATINUM SYSTEM IS INDICATED FOR USE AS AN ADJUNCTIVE DEVICE TO COMPLEMENT, NOT REPLACE, INFORMATION OBTAINED FROM STANDARD HOME GLUCOSE MONITORING DEVICES. THE DEXCOM G4 PLATINUM SYSTEM AIDS IN THE DETECTION OF EPISODES OFHYPERGLYCEMIA AND HYPOGLYCEMIA, FACILITATING BOTH ACUTE AND LONG-TERM THERAPY ADJUSTMENTS, WHICH MAY MINIMIZE THESE EXCURSIONS. INTERPRETATION OF THE DEXCOM G4 PLATINUM SYSTEM RESULTS SHOULD BE BASED ON THE TRENDS AND PATTERNS SEEN WITH SEVERAL SEQUENTIAL READINGS OVER TIME.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MDS. The earliest in FDA's data is P980022, decided Jun 15, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Dexcom, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.